Affimed GmbH news

• Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncology
• Scientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerging technologies

Heidelberg, Germany, June 30, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-onc

• AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status
• Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors
• In vivo studies of an AML murine model demonstrated anti-tumor efficacy; cynomolgus toxicology models showed pharmacodynamic activity with a well-to

• AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022
• AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and an increase in complete responses (CR) from 38%, reported in December, to 62% after a second cycle of therapy in 13 patients at the recommended phase 2 dose (RP2D) with encouraging signals on durabili

Heidelberg, Germany, May 26, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:00 p.m. Eastern Daylight Time / 19:00 Central European Time.

A live webcast of t

• Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors
• Design and rationale of the phase 1/2a study of AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors
• Design and rationale of the phase 1/2a study of AFM24 in combination with SNK01 autologous natural killer cells in patients with advanced EGFR-expressing solid tumors